Book a Meeting

Non-Fucosylated Anti-Human TNF (Certolizumab pegol) Therapeutic Antibody (CAT#: BioBet-1788ZP) Datasheet

Target
TNF
Isotype
IgG1/3
Description
Non-Fucosylated Anti-Human TNF (Certolizumab pegol) is a glycosylation-modified therapeutic biobetter antibody.
Indication
Crohn disease
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced TNF antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TNF
Full Name
tumor necrosis factor
Background
This gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine.
Alternative Names
DIF; TNFA; TNFSF2; TNLG1F; TNF-alpha
Gene ID
7124
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1/3
Antibody Clone
Certolizumab pegol
Host
Humanized afucosylated
Species Reactivity
Human
Description
This clone was generated using a stable CHO cell line with the FUT8 knockout gene. It was 100% non-fucosylated. In an in vitro cell-based ADCC assay, the afucosylated antibody clone showed significantly higher ADCC activity compared to its wild type version. The binding affinity of the non-fucosylated Fc variant antibody to Fc receptor is much higher than than the same antibody with fucosylated Fc. Robust and stable production of qualitative fully non-fucosylated therapeutic antibodies is achieved.
Indication
Crohn disease

Related Products

Non-fucosylated Anti-Human TNF (Golimumab) Therapeutic Antibody (CAT#: BioBet-026ZP)
Highly Galactosylated Anti-TNF (Placulumab) Antibody (CAT#: BioBet-GA-462ZP)
Highly Galactosylated Anti-TNF (Infliximab) Antibody (CAT#: BioBet-GA-021ZP)
Non-fucosylated Anti-Human TNF (Placulumab) Therapeutic Antibody (CAT#: BioBet-462ZP)
Non-fucosylated Anti-Human TNF (Nerelimomab) Therapeutic Antibody (CAT#: BioBet-461ZP)
Highly Galactosylated Anti-TNF (Golimumab) Antibody (CAT#: BioBet-GA-026ZP)
Highly Galactosylated Anti-TNF (Nerelimomab) Antibody (CAT#: BioBet-GA-461ZP)
Non-fucosylated Anti-Human TNF (Infliximab) Therapeutic Antibody (CAT#: BioBet-021ZP)

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.